Cardiac surveillance in immune checkpoint inhibitor therapy: Insights from the Essen Cardio‐oncology Registry

Key Result

Statin use was associated with reduced vascular toxicity in patients undergoing immune checkpoint inhibitor therapy, indicating a potential protective strategy.

Key Points

• The research aims to explore the relationship between statin use and vascular toxicity in patients undergoing immune checkpoint inhibitor therapy.
• Utilized data from the Essen Cardio-oncology Registry
• Assessed the association between statin use and vascular toxicity
• Identified high-risk population receiving immune checkpoint inhibitors
• Statin use is associated with reduced vascular toxicity
• Findings suggest statins may offer a protective effect in this population
• Further research is recommended to validate these preliminary observations